Zhengye Biotechnology
Zhengye Biotechnology's revenue fell 37.6% to CN¥116 million in fiscal 2025. Its operating margin was −60.6%, down from 8.8% a year earlier. Free cash flow was CN¥12 million, down 55.1%. The diluted share count rose 3.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
From fiscal 2022 to 2024, earnings per share fell 50.5% a year and net income 50.8% a year, with the share count about the same. Zhengye Biotechnology then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 10 | 16 | 20 | 52 |
| Debt incl. finance leases | — | 90 | 86 | 75 |
| Net debt (negative means net cash) | — | 74 | 66 | 23 |
| Net debt to EBITDA | — | 1.1x | 1.6x | — |
| Debt to equity | — | 0.3x | 0.3x | 0.3x |
| Interest coverage | 23.2x | 10.2x | 4.1x | −20.7x |
| Current ratio | — | 1.3x | 1.3x | 1.1x |
| Quick ratio | — | 0.9x | 0.9x | 0.8x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 3 of 9 |
| Rule of 40 | 0.6% | 2.8% | −27.0% |
| Altman Z'' | 3.58 | 3.73 | 1.49 |
| Accruals ratio | — | −6.0% | −17.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | Pass | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | — | — | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | — | Pass | Fail |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | 3 of 9 |
Compare
Put Zhengye Biotechnology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Zhengye Biotechnology | FY25 | −37.6% | −60.6% | 10.6% | −14.9% | — | 3 | |
| Gyre Therapeutics | FY25 | 10.2% | 9.8% | −0.1% | 9.7% | −3.8x | 4 | Compare |
| UroGen Pharma | FY25 | 21.4% | −113.7% | −148.2% | — | — | 2 | Compare |
| Zevra Therapeutics | FY25 | 350.9% | −59.1% | −2.3% | −218.8% | — | 5 | Compare |
| Zymeworks | FY25 | 38.9% | −87.3% | −32.6% | — | — | — | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 260 | 212 | 186 | 116 |
| Revenue growth | — | −18.7% | −11.9% | −37.6% |
| Gross profit | 148 | 118 | 91 | 24 |
| Research and development | 13 | 12 | 13 | 18 |
| Operating income | 66 | 45 | 16 | −70 |
| Net income | 47 | 32 | 11 | −70 |
| Diluted EPS (CNY) | 1.02 | 0.69 | 0.25 | — |
| Diluted shares (millions) | 46 | 46 | 46 | 47 |
| Cash flow | ||||
| Cash from operations | 17 | 48 | 41 | 13 |
| Capital expenditure | 27 | 7 | 14 | 1 |
| Free cash flow | −10 | 41 | 27 | 12 |
| Dividends paid | 21 | 40 | 16 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | — |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 10 | 16 | 20 | 52 |
| Debt incl. finance leases | — | 90 | 86 | 75 |
| Total assets | — | 500 | 493 | 436 |
| Total liabilities | — | 161 | 141 | 130 |
| Shareholders' equity | 357 | 273 | 284 | 250 |
| Margins and ratios | ||||
| Gross margin | 56.8% | 55.5% | 49.0% | 20.5% |
| Operating margin | 25.3% | 21.2% | 8.8% | −60.6% |
| Net margin | 18.0% | 14.9% | 6.1% | −60.0% |
| Free cash flow margin | −3.8% | 19.3% | 14.7% | 10.6% |
| Rule of 40 (growth + FCF margin) | — | 0.6% | 2.8% | −27.0% |
| Return on capital | — | — | 3.7% | −14.9% |
| Return on equity | — | — | 4.1% | −26.1% |
| Return on assets | — | — | 2.3% | −15.0% |
| Net debt to EBITDA | — | 1.1x | 1.6x | — |